KBC Group’s Cytokinetics CYTK Stock Holding History

KBC Group’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$229K	Hold	3,470	–	–	﹤0.01%	935
2025 Q4	$220K	Hold	3,470	–	–	﹤0.01%	887
2025 Q3	$191K	Hold	3,470	–	–	﹤0.01%	923
2025 Q2	$115K	Sell	3,470 -1,903	-35%	-$66.2K	﹤0.01%	1112
2025 Q1	$216K	Buy	5,373 +239	+5%	+$11K	﹤0.01%	1026
2024 Q4	$242K	Buy	5,134 +1,902	+59%	+$98.8K	﹤0.01%	1032
2024 Q3	$171K	Buy	3,232 +851	+36%	+$47.4K	﹤0.01%	999
2024 Q2	$129K	Buy	2,381 +362	+18%	+$21.9K	﹤0.01%	1045
2024 Q1	$142K	Sell	2,019 -327	-14%	-$25.3K	﹤0.01%	968
2023 Q4	$196K	Hold	2,346	–	–	﹤0.01%	848
2023 Q3	$69K	Sell	2,346 -5,080	-68%	-$169K	﹤0.01%	1192
2023 Q2	$242K	Sell	7,426 -427	-5%	-$15.8K	﹤0.01%	885
2023 Q1	$276K	Hold	7,853	–	–	﹤0.01%	886
2022 Q4	$360K	Hold	7,853	–	–	﹤0.01%	809
2022 Q3	$380K	Buy	7,853 +1,374	+21%	+$66.1K	﹤0.01%	811
2022 Q2	$255K	Buy	6,479 +3,794	+141%	+$153K	﹤0.01%	919
2022 Q1	$99K	Buy	+2,685	New	+$95.4K	﹤0.01%	1193

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

KBC Group's CYTK Position: Q1 2026 in Review

KBC Group held its Cytokinetics (CYTK) position steady in Q1 2026 at 3,470 shares worth $229K. The position accounts for ﹤0.01% of the portfolio, ranked #935.

KBC Group first reported a position in CYTK in Q1 2022 and has held it in 17 quarters since. The position peaked at $380K in Q3 2022. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

KBC Group held 3,470 shares of Cytokinetics worth $229K as of Q1 2026.
KBC Group left its Cytokinetics share count unchanged in Q1 2026.
Cytokinetics made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #935 holding.
KBC Group first reported a position in Cytokinetics in Q1 2022 and has held it in 17 quarters since.
KBC Group's Cytokinetics position peaked at $380K in Q3 2022.
439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.